Literature DB >> 31621112

Blockade of IL-4Rα inhibits group 2 innate lymphoid cell responses in asthma patients.

Gargi Patel1, Jiexue Pan2, Longyun Ye2, Xiaofei Shen2, Daniel Rosloff1, Shanti S D'Souza2, Ivan Ting Hin Fung2, Jocylen Celstin1, Wei Sun2, Poornima Sankar2, Yuanyue Zhang2, Muhammad Asghar Pasha1, Qi Yang1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31621112      PMCID： PMC6994377          DOI： 10.1111/cea.13514

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN： 0954-7894            Impact factor:   5.018


× No keyword cloud information.
  10 in total

1.  Basophils promote innate lymphoid cell responses in inflamed skin.

Authors:  Brian S Kim; Kelvin Wang; Mark C Siracusa; Steven A Saenz; Jonathan R Brestoff; Laurel A Monticelli; Mario Noti; Elia D Tait Wojno; Thomas C Fung; Masato Kubo; David Artis
Journal:  J Immunol       Date:  2014-08-25       Impact factor: 5.422

2.  Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Authors:  Mario Castro; Jonathan Corren; Ian D Pavord; Jorge Maspero; Sally Wenzel; Klaus F Rabe; William W Busse; Linda Ford; Lawrence Sher; J Mark FitzGerald; Constance Katelaris; Yuji Tohda; Bingzhi Zhang; Heribert Staudinger; Gianluca Pirozzi; Nikhil Amin; Marcella Ruddy; Bolanle Akinlade; Asif Khan; Jingdong Chao; Renata Martincova; Neil M H Graham; Jennifer D Hamilton; Brian N Swanson; Neil Stahl; George D Yancopoulos; Ariel Teper
Journal:  N Engl J Med       Date:  2018-05-21       Impact factor: 91.245

3.  Group 2 innate lymphoid cells mediate ozone-induced airway inflammation and hyperresponsiveness in mice.

Authors:  Qi Yang; Moyar Q Ge; Blerina Kokalari; Imre G Redai; Xinxin Wang; David M Kemeny; Avinash Bhandoola; Angela Haczku
Journal:  J Allergy Clin Immunol       Date:  2015-08-15       Impact factor: 10.793

4.  Enhanced innate type 2 immune response in peripheral blood from patients with asthma.

Authors:  Kathleen R Bartemes; Gail M Kephart; Stephanie J Fox; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2014-09       Impact factor: 10.793

5.  Group 2 innate lymphoid cells promote airway hyperresponsiveness through production of VEGFA.

Authors:  Xiaofei Shen; Muhammad Asghar Pasha; Kelsi Hidde; Adil Khan; Mingwei Liang; Wenxian Guan; Yitao Ding; Angela Haczku; Qi Yang
Journal:  J Allergy Clin Immunol       Date:  2018-01-31       Impact factor: 10.793

Review 6.  Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.

Authors:  William Busse; Geoffrey Chupp; Hiroyuki Nagase; Frank C Albers; Scott Doyle; Qin Shen; Daniel J Bratton; Necdet B Gunsoy
Journal:  J Allergy Clin Immunol       Date:  2018-09-08       Impact factor: 10.793

7.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.

Authors:  Kian Fan Chung; Sally E Wenzel; Jan L Brozek; Andrew Bush; Mario Castro; Peter J Sterk; Ian M Adcock; Eric D Bateman; Elisabeth H Bel; Eugene R Bleecker; Louis-Philippe Boulet; Christopher Brightling; Pascal Chanez; Sven-Erik Dahlen; Ratko Djukanovic; Urs Frey; Mina Gaga; Peter Gibson; Qutayba Hamid; Nizar N Jajour; Thais Mauad; Ronald L Sorkness; W Gerald Teague
Journal:  Eur Respir J       Date:  2013-12-12       Impact factor: 16.671

8.  Human group 2 innate lymphoid cells do not express the IL-5 receptor.

Authors:  Adam K A Wright; Cathryn Weston; Batika M J Rana; Christopher E Brightling; David J Cousins
Journal:  J Allergy Clin Immunol       Date:  2017-05-10       Impact factor: 10.793

9.  MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion.

Authors:  Christopher J Oliphant; You Yi Hwang; Jennifer A Walker; Maryam Salimi; See Heng Wong; James M Brewer; Alexandros Englezakis; Jillian L Barlow; Emily Hams; Seth T Scanlon; Graham S Ogg; Padraic G Fallon; Andrew N J McKenzie
Journal:  Immunity       Date:  2014-07-31       Impact factor: 31.745

10.  ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma.

Authors:  Q N Yu; Y B Guo; X Li; C L Li; W P Tan; X L Fan; Z L Qin; D Chen; W P Wen; S G Zheng; Q L Fu
Journal:  Allergy       Date:  2018-09       Impact factor: 13.146
  10 in total
  7 in total

1.  Innate Lymphoid Cells in Airway Inflammation.

Authors:  M Asghar Pasha; Qi Yang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  ILCs and Allergy.

Authors:  Hiroki Kabata; Yasutaka Motomura; Tsuyoshi Kiniwa; Tetsuro Kobayashi; Kazuyo Moro
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 3.  Group 2 innate lymphoid cells in nasal polyposis.

Authors:  Whitney W Stevens; Atsushi Kato
Journal:  Ann Allergy Asthma Immunol       Date:  2020-08-08       Impact factor: 6.347

4.  Rituximab and dupilumab improve eosinophilic granulomatosis with polyangiitis with multiple pulmonary thrombi.

Authors:  Sei Adachi; Chiyako Oshikata; Takeshi Kaneko; Naomi Tsurikisawa
Journal:  Allergy Asthma Clin Immunol       Date:  2022-02-26       Impact factor: 3.406

Review 5.  The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma.

Authors:  Takahiro Matsuyama; Hiromi Matsuyama; Yoichi Dotake; Koichi Takagi; Kentaro Machida; Hiromasa Inoue
Journal:  Front Immunol       Date:  2022-07-13       Impact factor: 8.786

6.  Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis.

Authors:  Shunya Tanaka; Taisuke Tsuji; Shinsuke Shiotsu; Tatsuya Yuba; Noriya Hiraoka
Journal:  Cureus       Date:  2022-05-22

7.  Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: A case report.

Authors:  Yoshiro Kai; Masanori Yoshikawa; Masayuki Matsuda; Kentaro Suzuki; Masato Takano; Kazuya Tanimura; Nobuhiro Fujioka; Yukio Fujita; Shigeo Muro
Journal:  Respir Med Case Rep       Date:  2022-08-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.